Drug Trial Radar · NCT04419623
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Last checked: Nov 19, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jul 9, 2020
Primary completion
Sep 22, 2020
Study completion Dec 15, 2020
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.
Conditions
- COVID-19
- Sars-CoV2
- Cancer
- Solid Tumor
- Carcinoma
- Blood Cancer
Interventions
TL-895Drug
TL-895, administered by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended dose of TL-895Time frame: After the day 14 of the 6th subject per dose level
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Georgia Cancer Center
Augusta, Georgia
The Ohio State Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.